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Background: Acute exacerbations are major drivers of COPD deterioration. However, limited 
data are available for the prevalence of severe exacerbations and impact of asthma on severe 
exacerbations, especially in patients with mild-to-moderate COPD.
Methods: Patients with mild-to-moderate COPD (40 years) were extracted from Korean 
National Health and Nutrition Examination Survey data (2007–2012) and were linked to 
the national health insurance reimbursement database to obtain medical service utilization 
records.
Results: Of the 2,397 patients with mild-to-moderate COPD, 111 (4.6%) had severe exacer-
bations over the 6 years (0.012/person-year). Severe exacerbations were more frequent in the 
COPD patients with concomitant self-reported physician-diagnosed asthma compared with only 
COPD patients (P0.001). A multiple logistic regression presented that asthma was an inde-
pendent risk factor of severe exacerbations in patients with mild-to-moderate COPD regardless 
of adjustment for all possible confounding factors (adjusted odds ratio, 1.67; 95% confidence 
interval, 1.002–2.77, P=0.049). In addition, age, female, poor lung function, use of inhalers, 
and low EuroQoL five dimensions questionnaire index values were independently associated 
with severe exacerbation in patients with mild-to-moderate COPD.
Conclusion: In this population-based study, the prevalence of severe exacerbations in patients 
with mild-to-moderate COPD was relatively low, compared with previous clinical interven-
tional studies. Coexisting asthma significantly impacted the frequency of severe exacerbations 
in patients with mild-to-moderate COPD, suggesting application of an exacerbation preventive 
strategy in these patients.
Keywords: bronchial asthma, chronic obstructive pulmonary disease, acute exacerbation
Introduction
Acute exacerbations of COPD are associated with a decline in lung function,1,2 reduced 
health-related quality of life (QoL),3,4 and high morbidity and mortality.5–9 Moreover, 
~50%-75% of health care service costs for COPD are attributed to acute exacerbations, 
particularly severe episodes requiring hospitalization.10 To date, vigorous efforts have 
been made to evaluate the risk factors for exacerbation of COPD, and the important 
determinants of frequent exacerbations, such as history of exacerbation,11,12 severe 
airflow limitation,11,12 or chronic bronchitis,13 were found in previous studies.
Bronchial asthma has received attention as a risk factor for frequent exacerba-
tion of COPD. A primary care population study showed that comorbidities including 
bronchial asthma are independent factors for moderate-to-severe exacerbations over 1 
year in patients with COPD.14 Furthermore, asthma-COPD overlap syndrome (ACOS) 
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is related to increased frequency and severity of exacerba-
tions and hospitalizations.15,16 Given that decline of lung 
function is faster in mild-to-moderate COPD patients than 
in patients with severe or very severe COPD17 and exacer-
bations accelerate the deterioration in lung function,1,2 it is 
necessary to explore whether bronchial asthma is associated 
with severe exacerbations in COPD patients with mild-to-
moderate airflow limitations. However, as patients with 
mild-to-moderate COPD have lower rates of hospital use 
and relatively infrequent severe exacerbations compared with 
those with severe COPD, data from clinical interventional 
studies are limited.
A moderate exacerbation is defined when a patient with 
an exacerbation is treated with specific antibiotics or oral 
corticosteroids.18 COPD patients often receive prescription 
of both antibiotics and prednisone for COPD exacerbation 
action plan in the clinics and are educated to increase the 
frequency of inhaler use or to initiate these medications 
on worsening symptoms including dyspnea, sputum color 
change, or sputum volume increase. Thus, the number of 
moderate exacerbations based on prescription records and 
event coding of National Health Insurance (NHI) data is 
probably inaccurate due to the possibility of steroid or anti-
biotic prescriptions for COPD exacerbation action plans or 
the possibility of an unrecorded exacerbation event. A severe 
exacerbation is defined as an exacerbation requiring hospital 
admission or a visit to the emergency department.18 As all 
diagnostic and medication records during a hospital admis-
sion or emergency department visit are sent to NHI for the 
reimbursement, the number of severe exacerbation based on 
NHI data is more reliable. Thus, our study concerns severe 
exacerbations as an outcome.
The purposes of this study were to investigate the fre-
quency of severe exacerbations in COPD patients having 
mild-to-moderate airflow limitations and to evaluate whether 
asthma is associated with severe exacerbations in patients 
with mild-to-moderate COPD using both the Korean National 
Health and Nutrition Examination Survey (KNHANES) 
and the NHI reimbursement databases during 2007–2012 
in Korea.
Methods
study design
The KNHANES (2007–2012) is a cross-sectional observa-
tional study conducted using complex and stratified multistage 
cluster sampling to select a representative nationwide sample 
of the noninstitutionalized Korean population. In addition, 
South Korea has a compulsory universal health insurance 
system that includes medical reimbursement records for the 
entire Korean population. The NHI reimbursement database 
provides a unique and advantageous mechanism for assessing 
the nationwide magnitude of an illness and consequent health 
care use. Two databases were linked, thus complementary 
information can be obtained through both databases.
We constructed a patient cohort from KNHANES using 
data obtained from January 2007 to December 2012 who 
were aged 40 years and were diagnosed with mild-to-
moderate COPD by spirometry (prebronchodilator ratio of 
forced expiratory volume in 1 second (FEV
1
) to forced vital 
capacity (FVC) of less than 0.70 and FEV
1
 of more than 
50% of the predicted value). Absolute values of FEV
1
 and 
FVC were obtained and percentage of the predicted values 
(% predicted) for FEV
1
 and FVC was calculated using the 
reference equation obtained based on analysis of a representa-
tive Korean sample.19 This cohort was linked to the NHI data 
to analyze their health care service utilization from January 
2007 to December 2012 (Figure 1). Since the annual rate of 
decline in FEV
1
 is reduced especially in Asian patients,20 we 
assumed that the change of lung function would be minimal 
for 6 years. Thus, for the COPD patients enrolled to the 
KNHANES in 2007, the outcome of severe exacerbation was 
prospectively assessed until 2012 for 6 years, and for those 
from the KNHANES in 2012, the outcome of severe exacer-
bation was retrospectively assessed to 2007 for 6 years.
Emergency department visits or hospitalizations requiring 
treatment with systemic corticosteroids and/or antibiotics 
were considered a severe exacerbation when the principal 
or secondary diagnosis was COPD (J42.x-J44.x [unspecified 
chronic bronchitis: J42.x, emphysema: J43.x, other COPD: 
J44.x], except unilateral pulmonary emphysema: J430) or a 
COPD-related disease (pneumonia: J12.x–J17.x, pulmonary 
thromboembolism: I26, I26.0, and I26.9, dyspnea: R06.0, 
or acute respiratory distress syndrome: J80) as from our 
previous studies.21–24 Medical utilization were excluded for 
analysis if they were not considered to be COPD-related.
We obtained information such as age, sex, body mass 
index (BMI), smoking history, physical activity, the EuroQoL 
five dimensions questionnaire (EQ-5D) index values, which 
range between 0 (worst imaginable health state) and 1 (best 
imaginable health state), and pulmonary function test results 
from the KNHANES database. The prevalence of self-reported 
physician-diagnosed diseases – ischemic heart disease, depres-
sive disorder, diabetes mellitus (DM), hypertension, atopic 
dermatitis, stroke, bronchial asthma, and previous pulmonary 
tuberculosis – were also obtained from questionnaire conducted 
by the KNHANES. Hospitalizations, emergency department 
visits, intensive care unit admissions, and medication service 
use were obtained from the NIH database. We also contained 
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the use of inhalers (long-acting beta
2
-agonist, long-acting 
muscarinic antagonist, or inhaled corticosteroid/long-acting 
beta
2
-agonist), which had been prescribed before the patients 
experienced severe exacerbations.
This study was approved by The National Evidence-
based Healthcare Collaborating Agency Ethics Committee 
of Korea. The requirement for informed consent from the 
patients was waived due to the retrospective nature of this 
study by the ethics review board.
statistical analysis
Data are presented as mean and standard deviation for 
continuous variables and as numbers (percentages) for cat-
egorical variables. The data were compared using Student’s 
t-test for continuous and Pearson’s χ2 test for categorical 
variables. To analyze an impact of FEV
1
 and EQ-5D index 
values on the severe exacerbations in mild-to-moderate 
COPD patients, we classified the patients into three groups 
based on FEV
1
 (those with FEV
1
% predicted 80%, those 
with 65% FEV
1
% predicted 80%, and those with 
50% FEV
1
% predicted 65%) and two groups based on 
EQ-5D index values (those with EQ-5D index values 0.9 
and those with EQ-5D index values 0.9) and analyzed these 
factors as categorical variables.
A multiple logistic regression model was used to adjust 
for potential confounding factors in severe exacerbations 
in COPD patients. Four models were constructed: Model 
1 was adjusted for age, sex, and BMI; Model 2 was addi-
tionally adjusted for pulmonary-related variables generally 
considered to be important in severe exacerbations in COPD 
(smoking history and severity of airflow limitation); Model 
3 additionally included extrapulmonary-related variables 
generally considered to be important in severe exacerba-
tions in COPD or extrapulmonary-related variables with 
P0.05 in the univariate analyses with considering multi-
collinearity (DM, cardiovascular disease [stroke, myocardial 
infarction, and angina pectoris], and QoL); finally, Model 
4 was additionally adjusted for use of inhalers with all of 
the above-mentioned variables. All tests were two-sided, 
and P0.05 was considered to indicate significance. All 
statistical analyses were performed using SAS ver. 9.2 (SAS 
Institute, Cary, NC, USA).
Results
clinical characteristics of patients
A total of 2,397 patients with mild-to-moderate COPD 
were identified from the KNHANES databases between 
2007 and 2012 (Figure 1). As shown in Table 1, there 
1+,
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Figure 1 Study flow chart and outcome assessment flow using KNHANES and NHI reimbursement database.
Note: Vertical arrows in the rectangle box indicate the year of enrollment from Knhanes. Dashed arrows in the rectangle box represent the retrospective assessment of 
nhi data and solid arrows in the rectangle box represent the prospective assessment of nhi data.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVc, forced vital capacity; Knhanes, Korean national health and nutrition examination survey; nhi, 
national health insurance.
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were 1,692 males (70.6%) and 705 females (29.4%) with 
a mean age of 63.5 years. Mean BMI was 23.5±2.9 kg/m2 
and 1,621 patients (67.6%) were current or ex-smokers. 
The common comorbidities were hypertension (n=847, 
35.3%), followed by DM (n=331, 13.8%), depressive disor-
der (n=296, 12.3%), and bronchial asthma (n=261, 10.9%). 
The mean FEV
1
/FVC and FEV
1
 were 60% and 2.3 L (78.6% 
predicted), respectively. Whereas 44.8% (1,075/2,397) of the 
patients had mild airflow limitations (FEV
1
 80% predicted), 
55.2% (1,322/2,397) had moderate airflow limitations 
(50% FEV
1
% predicted 80%). The mean EQ-5D index 
values were 0.9. Only 5.9% of mild-to-moderate COPD 
patients used inhalers such as long-acting muscarinic antago-
nist (3.4%, n=82) and inhaled corticosteroid/long-acting 
beta
2
-agonist (4.1%, n=98) before severe exacerbations.
Regarding COPD-related medical utilization, overall 
18.6% had history of medical service use over the duration 
of the study period.
comparison of clinical characteristics 
between patients with and without 
severe exacerbations
As shown in Figure 2, 95.4% of patients (n=2,286) had no 
history of a severe COPD exacerbation, whereas 4.6% of 
patients (n=111) experienced one or more severe exacer-
bations during the 6-year study period. The rate of severe 
exacerbations during the 6-year follow-up period was 0.012/
person-year.
Compared with patients without severe exacerbations 
during the study period, patients who suffered a severe exac-
erbation were more likely to be older (69.5 vs 63.2 years, 
P0.001), female (46.8% vs 28.6%, P0.001), nonsmokers 
(43.2% vs 30.6%, P=0.005), and more likely to have fewer 
days of high active physical activity per week (1.5 vs 
1.8 days, P=0.008) and fewer proportions of patients with 
EQ-5D index values 0.9 (29.7% vs 69.0%, P0.001). 
In addition, patients with severe exacerbations showed poorer 
lung function (mean FEV
1
, % predicted: 74.2% predicted vs 
78.8% predicted, P0.001) and used inhalers more (36.9% 
vs 4.4%, P0.001) than those without severe exacerbations. 
Comorbidities including DM (20.7% vs 13.5%, P=0.031) and 
bronchial asthma (25.2% vs 10.2%, P0.001) were more 
frequently observed in patients with severe exacerbations 
than in those without severe exacerbations during the 6-year 
study period. No differences were observed in BMI, smoking 
Table 1 Baseline characteristics (n=2,397)
N (%) or  
mean ± SD
age, years 63.5±11.9
sex, male 1,692 (70.6)
Body mass index, kg/m2 23.5±2.9
Body mass index 25 kg/m2 689 (28.7)
smoking historya
nonsmoker 747 (31.2)
current or ex-smoker 1,621 (67.6)
Pack-years 23.9±23.3
Previous pulmonary tuberculosis 323 (13.5)
comorbidities
hypertension 847 (35.3)
Diabetes mellitus 331 (13.8)
Depression 296 (12.3)
Bronchial asthma 261 (10.9)
coronary heart diseaseb 96 (4.0)
atopic dermatitis 69 (2.9)
stroke 66 (2.8)
Physical activity
Days of moderate active physical activity per week 2.3±2.1
Days of high active physical activity per week 1.8±1.7
Baseline pulmonary function test
FVc, l 3.6±0.9
FVc, % predicted 90.9±13.6
FeV1, l 2.3±0.6
FeV1, % predicted 78.6±13.7
FeV1/FVc 0.6±0.07
cOPD severity
FeV1% predicted 80% 1,075 (44.8)
65% FeV1% predicted 80% 924 (38.6)
50% FeV1% predicted 65% 398 (16.6)
eQ-5D index values 0.9±0.1
eQ-5D index values 0.9 1,611 (67.2)
Use of inhalers 141 (5.9)
laMa 82 (3.4)
laBa 0 (0)
ics/laBa 98 (4.1)
Notes: The data are presented as number (%) or mean and sD. aData of 29 patients 
are missed. bcoronary heart disease includes myocardial infarction and angina 
pectoris.
Abbreviations: EQ-5D, The EuroQoL five dimensions questionnaire; FEV1, forced 
expiratory volume in 1 second; FVc, forced vital capacity; ics, inhaled corticosteroid; 
laBa, long-acting beta2-agonist; laMa, long-acting muscarinic antagonist; sD, 
standard deviation.
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Figure 2 number of severe exacerbations in overall population over 6-year follow-up.
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history (pack-years), comorbidities including hypertension, 
depression, coronary heart disease, atopic dermatitis, stroke, 
and previous pulmonary tuberculosis, and days of moderate 
physical activity per week between patients with and without 
severe exacerbations during the study period (Table 2).
Factors associated with severe 
exacerbations in patients with mild-to-
moderate cOPD
Severe exacerbations were more frequent in COPD patients 
with concomitant bronchial asthma compared with COPD 
patients without concomitant bronchial asthma (10.7% vs 
3.9%, P0.001 and 0.027/person-year vs 0.010/person-year, 
P=0.004, Figure 3).
In the overall population, bronchial asthma (adjusted odds 
ratio [aOR], 1.96; 95% confidence interval [CI], 1.21–3.18, 
P=0.007) was independently associated with the develop-
ment of severe exacerbations after adjustment for all possible 
confounding factors except for use of inhalers (Model 3). 
With the addition of use of inhalers as a confounding factor 
(Model 4), the significance of bronchial asthma associated 
with the development of severe exacerbations persisted 
(aOR, 1.67; 95% CI, 1.002–2.77, P=0.049) (Figure 4). In 
addition, Model 4 showed that age (aOR, 1.04; 95% CI, 
1.02–1.06, P0.001), female (aOR, 1.82; 95% CI, 1.01–3.33, 
P=0.045), the severity of airflow limitations (50% FEV
1
, 
% predicted 65% vs FEV
1
, % predicted 80%, aOR, 1.93; 
95% CI, 1.15–3.24, P=0.013), the use of inhalers (aOR, 2.34; 
Table 2 comparison of characteristics between patients with and without severe exacerbations
Patients without  
severe exacerbations
(n=2,286, 95.4%)
Patients with severe 
exacerbations
(n=111, 4.6%)
P-value
age, yearsa 63.2±11.9 69.5±8.2 0.001
sex, male 1,633 (71.4) 59 (53.2) 0.001
Body mass index, kg/m2a 23.5±2.8 23.5±2.9 0.821
Body mass index 25 kg/m2 659 (28.8) 30 (27.0) 0.682
smoking historyb
nonsmoker 699 (30.6) 48 (43.2) 0.005
current or ex-smoker 1,559 (68.2) 62 (55.9)
Pack-yearsa 24.0±23.0 20.9±28.9 0.310
Previous pulmonary tuberculosis 304 (13.3) 19 (17.1) 0.250
comorbidities
Diabetes mellitus 308 (13.5) 23 (20.7) 0.031
hypertension 801 (35.0) 46 (41.4) 0.168
Depression 276 (12.1) 20 (18.0) 0.063
Bronchial asthma 233 (10.2) 28 (25.2) 0.001
coronary heart diseasec 92 (4.0) 4 (3.6) 0.825
atopic dermatitis 65 (2.8) 4 (3.6) 0.640
stroke 61 (2.7) 5 (4.5) 0.248
Physical activity
Days of moderate active physical activity per weeka 2.3±2.1 2.3±2.1 0.862
Days of high active physical activity per weeka 1.8±1.7 1.5±1.4 0.008
Baseline pulmonary function test
FVc, la 3.6±0.9 3.1±0.9 0.001
FVc, % predicteda 91.0±13.6 87.8±14.0 0.016
FeV1, l
a 2.3±0.6 1.8±0.6 0.001
FeV1, % predicted
a 78.8±13.6 74.2±14.4 0.001
FeV1/FVc, %
a 0.6±0.1 0.6±0.1 0.001
cOPD severity 0.001
FeV1, % predicted 80% 1,034 (45.2) 41 (36.9)
65% FeV1, % predicted 80% 888 (38.9) 36 (32.5)
50% FeV1, % predicted 65% 364 (15.9) 34 (30.6)
eQ-5D index values 0.9 1,578 (69.0) 33 (29.7) 0.001
Use of inhalers 100 (4.4) 41 (36.9) 0.001
Notes: The data are presented as number (%) or mean and standard deviation. aThese data are analyzed by using student’s t-test. bData of 29 patients are missed including 
28 patients without severe exacerbations and one patient with severe exacerbation. ccoronary heart disease includes myocardial infarction and angina pectoris.
Abbreviations: EQ-5D, The EuroQoL five dimensions questionnaire; FEV1, forced expiratory volume in 1 second; FVc, forced vital capacity.
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95% CI, 1.25–4.38, P=0.008) and poor QoL (EQ-5D index 
values 0.9 vs EQ-5D index values 0.9, aOR, 3.47; 95% 
CI, 2.22–5.43, P0.001) were correlated with the develop-
ment of severe exacerbations in mild-to-moderate COPD 
patients (Table 3).
Discussion
This is the first population-based observational study using 
a 6-year nationwide database to explore the prevalence of 
severe exacerbations in mild-to-moderate COPD. We found 
that 4.6% of patients with mild-to-moderate COPD experi-
enced more than one severe exacerbation requiring a hospital 
admission or visit to the emergency department with admin-
istration of systemic corticosteroids and/or antibiotics over 
the 6-year study period. In addition, we provided robust data 
showing that coexisting bronchial asthma was associated with 
severe exacerbation in mild-to-moderate COPD patients.
This study evaluated the prevalence of severe exacer-
bations in a representative nationwide sample with mild-
to-moderate COPD, which might reflect the real prevalence 
of the general COPD population including both symptom-
atic and nonsymptomatic patients. The prevalence rates of 
severe exacerbations were 0.009/person-year in patients with 
FEV
1
 80% predicted and 0.013/person-year in patients with 
50% predicted FEV
1
 80% predicted, which is approxi-
mately one-tenth of that reported previously for patients 
with moderate COPD, which was estimated at 0.11–0.2/
person-year.11,25 This substantial difference can be explained 
Figure 4 association between asthma and severe exacerbations in mild-to-moderate cOPD patients. Diamonds and whiskers show odds ratio and 95% ci values, 
respectively. Model 1 was adjusted for age, sex, and BMi; Model 2 was additionally adjusted for pulmonary-related variables generally considered to be important in severe 
exacerbations in COPD (smoking history and severity of airflow limitation); Model 3 additionally included extrapulmonary-related variables generally considered to be 
important in severe exacerbations in cOPD or extrapulmonary-related variables with P0.05 in the univariate analyses with considering multicollinearity (diabetes mellitus, 
cardiovascular disease [stroke, myocardial infarction, and angina pectoris], and quality of life); finally, Model 4 was additionally adjusted for use of inhalers with all of the above 
mentioned variables.
Abbreviations: BMI, body mass index; CI, confidence interval.
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Figure 3 The comparison of severe exacerbation between cOPD patients with coexisting self-reported physician-diagnosed bronchial asthma and those with cOPD only.
Notes: (A) Percentage of patients with severe exacerbations and (B) number of severe exacerbations/person-year.
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of this study with a prolonged follow-up of 6 years, as 
1 year is insufficient to obtain the frequency of exacerba-
tions in patients with mild-to-moderate COPD. Furthermore, 
we investigated utilization of the health care system in all 
patients with mild-to-moderate COPD, as confirmed by 
spirometry in the KNHANES, which overcomes a limitation 
of a previous study that the true population of patients with 
a milder airflow obstruction (mild-to-moderate COPD) may 
be underestimated, as these patients would not require health 
care or undergo spirometry.14
We observed that severe exacerbations in mild-to-moderate 
COPD patients are more frequent as FEV
1
 decreases and the 
EQ-5D index representing health-related QoL is low. It is 
well established that exacerbations deteriorate lung function 
and health-related QoL and, in turn, poor lung function and 
low QoL are risk factors for subsequent severe exacerba-
tions in patients with moderate-to-severe COPD.8,11,12,25,27–30 
In particular, EQ-5D index is related to poor clinical outcome 
of exacerbations.31 We extended these independent associa-
tions to patients with mild COPD, suggesting that mild COPD 
patients with relatively preserved lung function showed 
characteristics similar to those with moderate-to-severe 
COPD. In addition, we found that the use of inhalers was 
associated with severe exacerbations in mild-to-moderate 
COPD patients. A recent retrospective observational study 
showed that COPD patients with more symptoms increased 
the likelihood of receiving inhalers in the Optimum Patient 
Care Research Database, which is a quality-controlled, 
longitudinal, primary care respiratory database.32 Thus, the 
use of inhalers in the present study might indicate more 
symptomatic COPD patients with mild-to-moderate airflow 
limitation in the real practice.
There are several limitations in this study. First, as lung 
function test were performed only during the time of enroll-
ment to KNHANES, some patients who were classified as 
moderate COPD from data of 2012 KNHANES would have 
mild COPD at 2007. In addition, the events of severe exac-
erbation were not assessed prospectively for all patients. In 
other words, some events of severe exacerbation would be 
assessed retrospectively from the point of the risk assessment 
obtained from KNHANES, as such the directionality of the 
relationship between severe exacerbation and lung function 
or EQ-5D could be uncertain. It is possible that severe exac-
erbation caused poor lung function and low EQ-5D index 
but reverse causation was also possible. However, as severe 
exacerbation cannot cause bronchial asthma to develop and 
there was self-reported past history of physician-diagnosed 
bronchial asthma, the effect of our study model for the 
Table 3 Multivariate analysis for factors associated with severe 
exacerbations in mild-to-moderate cOPD patients
All patients (n=2,397)
aOR (95% CI) P-value
age, years 1.04 (1.02–1.06) 0.001
sex, female 1.82 (1.01–3.33) 0.045
Body mass index, kg/m2 1.0 (0.93–1.07) 0.954
smoking historya
nonsmokerc 1.0
current or ex-smoker 1.02 (0.57–1.82) 0.961
comorbidities
Diabetes mellitus 1.44 (0.87–2.38) 0.157
cardiovascular diseaseb 0.89 (0.42–1.86) 0.752
Bronchial asthma 1.67 (1.002–2.77) 0.049
Severity of airflow limitation
FeV1, % predicted 80%
c 1.0
65% FeV1, % predicted 80% 1.14 (0.70–1.85) 0.599
50% FeV1, % predicted 65% 1.93 (1.15–3.24) 0.013
Quality of life
eQ-5D index values 0.9c 1.0
eQ-5D index values 0.9 3.47 (2.22–5.43) 0.001
Use of inhalers 2.34 (1.25–4.38) 0.008
Notes: aData of 29 patients are missed. bcardiovascular disease includes stroke, 
myocardial infarction, and angina pectoris. csubjects in this category served as the 
reference group.
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; EQ-5D, The 
EuroQoL five dimensions questionnaire; FEV1, forced expiratory volume in 1 second.
by the composition of symptomatic patients. About half of 
the patients in the ECLIPSE study had symptoms (modified 
Medical Research Council score 2) and more than half of 
the patients in the TORCH study had a history of inhaler 
treatment for COPD,11,26 whereas 81.4% of our subjects had 
no history of COPD-related medical service use. When we 
restricted subjects who ever used COPD-related medical 
service, the prevalence of severe exacerbation was 0.062/
person-year, which is comparable to the rates in the ECLIPSE 
and TORCH studies considering that our study included 
patients with mild COPD.
We showed that coexisting bronchial asthma was inde-
pendently associated with a higher risk for severe exac-
erbation. Our data agree with a previous study regarding 
ACOS, which showed that patients with ACOS experience 
up to 1.9-fold more severe COPD exacerbations than those 
with COPD alone.16 Subjects with ACOS in the PLATINO 
study had a higher risk for hospitalization due to exacerba-
tions at a prevalence ratio of 4.11, compared to those with 
only COPD.15 In addition, this observation replicates earlier 
findings from a large retrospective cohort study showing 
that bronchial asthma is one of the independent predictors 
of moderate-to-severe exacerbation over a 1-year follow-up 
in a primary care population.14 We extended the findings 
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association between severe exacerbation and bronchial 
asthma would be minimal. Third, the other prognosis associ-
ated with severe exacerbation, such as lung function decline 
or mortality, were not assessed in the present study. Further 
studies to evaluate impact of concomitant bronchial asthma 
with COPD on natural course of disease are needed. Finally, 
this study was performed in a single country in Asia and to 
generalize our findings, additional studies in other countries 
are necessary.
In conclusion, the prevalence of severe exacerbations in 
patients with mild-to-moderate COPD was 0.012/person-
year in this population-based observational study using a 
nationwide database. Bronchial asthma was an independent 
factor associated with severe exacerbations in patients with 
mild-to-moderate COPD. Given the impact of coexisting 
bronchial asthma on the frequency of severe exacerbations 
in patients with mild-to-moderate COPD, exacerbation pre-
ventive strategies are necessary in patients with a bronchial 
asthma history across COPD disease severities.
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